Napredna pretraga

Pregled bibliografske jedinice broj: 546555

Lapatinib in the treatment of HER-2 overexpressing breast cancer


Vrdoljak, Eduard; Boban, Marijo; Ban, Marija
Lapatinib in the treatment of HER-2 overexpressing breast cancer // Journal of B.U.O.N, 16 (2011), 3; 393-399 (međunarodna recenzija, članak, znanstveni)


Naslov
Lapatinib in the treatment of HER-2 overexpressing breast cancer

Autori
Vrdoljak, Eduard ; Boban, Marijo ; Ban, Marija

Izvornik
Journal of B.U.O.N (1107-0625) 16 (2011), 3; 393-399

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Lapatinib; breast cancer

Sažetak
Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have progressed on treatment with trastuzumab, taxanes and anthracyclines. Moreover, when given with letrozole in postmenopausal patients with estrogen receptor (ER) and HER-2 positive disease it induces clinically meaningful benefit. Recently presented neoadjuvant data suggests an important place for the combination of trastuzumab and lapatinib in the therapy of early HER-2 positive breast cancer. This article reviews the current status and future perspectives of lapatinib.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekt / tema
216-0000000-0484 - Dvostruki model ovarijalne kancerogeneze - molekularna i morfološka studija (Snježana Tomić, )

Ustanove
Medicinski fakultet, Split

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • MEDLINE